Antiviral therapeutics for the treatment of Ebola virus infection

Current Opinion in Pharmacology

Volumn 30, Issue , 2016, Pages 138-143

  Cardile, Anthony P ^a   Downey, Lydia G ^a   Wiseman, Perry D ^a   Warren, Travis K ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTISENSE OLIGONUCLEOTIDE; AVI 6002; AVI 7537; AVI 7539; BRINCIDOFOVIR; FAVIPIRAVIR; GALIDESIVIR; GS 5734; MORPHOLINO OLIGONUCLEOTIDE; RNA DIRECTED RNA POLYMERASE INHIBITOR; SMALL INTERFERING RNA; TKM 130803; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

AFRICA; ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MEDICAL ETHICS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECTS; ETHICS; HEMORRHAGIC FEVER, EBOLA; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIROLOGY;

AFRICA, WESTERN; ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DRUG DESIGN; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84987956532     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.08.016     Document Type: Review

References (35)

1. 1 World Health Organization. Ebola Virus Situation report. Available at: http://apps.who.int/iris/bitstream/10665/208883/1/ebolasitrep_10Jun2016_eng.pdf?ua=1 (Accessed on June 25, 2016).
2. 2 Kuhn, J.H., Andersen, K.G., Baize, S., Bao, Y., Bavari, S., Berthet, N., Blinkova, O., Brister, J.R., Clawson, A.N., Fair, J., et al. Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses 6 (2014), 4760–4799.
3. 3 Cardile, A., Mayers, D., Bavari, S., Emerging options in development for treatment of filovirus infections. Drugs Future 40 (2015), 727–738.
4. 4 Mendoza, E.J., Qiu, X., Kobinger, G.P., Progression of Ebola therapeutics during the 2014–2015 outbreak. Trends Mol Med 22 (2016), 164–173.
5. 5 Friedrich, B.M., Trefry, J.C., Biggins, J.E., Hensley, L.E., Honko, A.N., Smith, D.R., Olinger, G.G., Potential vaccines and post-exposure treatments for filovirus infections. Viruses 4 (2012), 1619–1650.
6. 6 Kole, R., Krainer, A.R., Altman, S., RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11 (2012), 125–140.
7. 7 Spurgers, K.B., Sharkey, C.M., Warfield, K.L., Bavari, S., Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 78 (2008), 26–36.
8. 8 Heald, A.E., Iversen, P.L., Saoud, J.B., Sazani, P., Charleston, J.S., Axtelle, T., Wong, M., Smith, W.B., Vutikullird, A., Kaye, E., Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother 58 (2014), 6639–6647.
9. 9 Warren, T.K., Whitehouse, C.A., Wells, J., Welch, L., Heald, A.E., Charleston, J.S., Sazani, P., Reid, S.P., Iversen, P.L., Bavari, S., A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection. MBio, 6, 2015.
10. 10 Geisbert, T.W., Hensley, L.E., Kagan, E., Yu, E.Z., Geisbert, J.B., Daddario-DiCaprio, K., Fritz, E.A., Jahrling, P.B., McClintock, K., Phelps, J.R., et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193 (2006), 1650–1657.
11. 11 Thi, E.P., Mire, C.E., Lee, A.C., Geisbert, J.B., Zhou, J.Z., Agans, K.N., Snead, N.M., Deer, D.J., Barnard, T.R., Fenton, K.A., et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 521 (2015), 362–365.
12. 12•• Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H.K., et al. Experimental treatment of ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med, 13, 2016, e1001997 These articles describe efficacy studies against Ebola virus conducted during the West Africa outbreak that are available to date in the peer reviewed literature.
13. 13 Taylor, R., Kotian, P., Warren, T., Panchal, R., Bavari, S., Julander, J., Dobo, S., Rose, A., El-Kattan, Y., Taubenheim, B., et al. BCX4430 — a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health 9 (2016), 220–226.
14. 14 Warren, T.K., Wells, J., Panchal, R.G., Stuthman, K.S., Garza, N.L., Van Tongeren, S.A., Dong, L., Retterer, C.J., Eaton, B.P., Pegoraro, G., et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508 (2014), 402–405.
15. 15 McMullan, L.K., Flint, M., Dyall, J., Albarino, C., Olinger, G.G., Foster, S., Sethna, P., Hensley, L.E., Nichol, S.T., Lanier, E.R., et al. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. Antiviral Res 125 (2016), 71–78.
16. 16 Florescu, D.F., Kalil, A.C., Hewlett, A.L., Schuh, A.J., Stroher, U., Uyeki, T.M., Smith, P.W., Administration of brincidofovir and convalescent plasma in a patient with ebola virus disease. Clin Infect Dis 61 (2015), 969–973.
17. 17 Chimerix, inc. Brincidofovir Will Not Be Considered in Further Clinical Trials in Ebola Virus Disease. Available at: http://ir.chimerix.com/releasedetail.cfm?releaseid=893927. (Accessed on: October 11, 2015).
18. 18 Oestereich, L., Rieger, T., Neumann, M., Bernreuther, C., Lehmann, M., Krasemann, S., Wurr, S., Emmerich, P., de Lamballerie, X., Olschlager, S., et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis, 8, 2014, e2804.
19. 19 Smither, S.J., Eastaugh, L.S., Steward, J.A., Nelson, M., Lenk, R.P., Lever, M.S., Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 104 (2014), 153–155.
20. 20•• Sissoko, D., Laouenan, C., Folkesson, E., M'Lebing, A.B., Beavogui, A.H., Baize, S., Camara, A.M., Maes, P., Shepherd, S., Danel, C., et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med, 13, 2016, e1001967 These articles describe efficacy studies against Ebola virus conducted during the West Africa outbreak that are available to date in the peer reviewed literature.
21. 21 Warren, T.K., Jordan, R., Lo, M.K., Ray, A.S., Mackman, R.L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H.C., et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531 (2016), 381–385.
22. 22 Farge, E., Guinea's last Ebola case, a baby girl, leaves hospital. 2015 Available at: http://www.reuters.com/article/us-health-ebola-guinea-idUSKBN0TH0PB20151128. Accessed on March 5, 2016.
23. 23 Jacobs, M., Rodger, A., Bell, D.J., Bhagani, S., Cropley, I., Filipe, A., Gifford, R.J., Hopkins, S., Hughes, J., Jabeen, F., et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388 (2016), 498–503.
24. 24 Gilead, Gilead Pipeline. 2016 Available at: http://www.gilead.com/research/pipeline. Accessed on March 5.
25. 25 Cohen, J., Enserink, M., As Ebola epidemic draws to a close, a thin scientific harvest. Science 351 (2016), 12–13.
26. 26•• van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M.G., Gallian, P., Baize, S., Horby, P.W., Raoul, H., Magassouba, N., Antierens, A., et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374 (2016), 33–42 These articles describe efficacy studies against Ebola virus conducted during the West Africa outbreak that are available to date in the peer reviewed literature.
27. 27 Luczkowiak, J., Arribas, J.R., Gomez, S., Jimenez-Yuste, V., de la Calle, F., Viejo, A., Delgado, R., Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus Res 213 (2016), 224–229.
28. 28 Dye, J.M., Herbert, A.S., Kuehne, A.I., Barth, J.F., Muhammad, M.A., Zak, S.E., Ortiz, R.A., Prugar, L.I., Pratt, W.D., Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 109 (2012), 5034–5039.
29. 29 Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J.B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514 (2014), 47–53.
30. 30•• Davey, R., PREVAIL II: A Randomized Controlled Trial of ZMapp™ in Acute Ebola Virus Infection. Available at: http://www.croiwebcasts.org/console/player/29572?mediaType=audio&. Accessed on March 10, 2016, 2016 PREVAILII study that evaluated the efficacy of ZMapp is described at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI).
31. 31• Dodd, L.E., Proschan, M.A., Neuhaus, J., Koopmeiners, J.S., Neaton, J., Beigel, J.D., Barrett, K., Lane, H.C., Davey, R.T. Jr., Design of a randomized controlled-trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM study. J Infect Dis 213 (2016), 1906–1913 Describes the design of the PREVAILII study which evaluated ZMapp.
32. 32 Furuyama, W., Marzi, A., Nanbo, A., Haddock, E., Maruyama, J., Miyamoto, H., Igarashi, M., Yoshida, R., Noyori, O., Feldmann, H., et al. Discovery of an antibody for pan-ebolavirus therapy. Sci Rep, 6, 2016, 20514.
33. 33 Howell, K.A., Qiu, X., Brannan, J.M., Bryan, C., Davidson, E., Holtsberg, F.W., Wec, A.Z., Shulenin, S., Biggins, J.E., Douglas, R., et al. Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep 15 (2016), 1514–1526.
34. 34 Yen, B.C., Basler, C.F., Effects of filovirus interferon antagonists on responses of human monocyte-derived dendritic cells to RNA virus infection. J Virol 90 (2016), 5108–5118.
35. 35 Smith, L.M., Hensley, L.E., Geisbert, T.W., Johnson, J., Stossel, A., Honko, A., Yen, J.Y., Geisbert, J., Paragas, J., Fritz, E., et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 208 (2013), 310–318.